Open Access

IL‑37 relieves allergic inflammation by inhibiting the CCL11 signaling pathway in a mouse model of allergic rhinitis

  • Authors:
    • Huijia Lei
    • Yiqing Sun
    • Shiming Quan
  • View Affiliations

  • Published online on: July 29, 2020     https://doi.org/10.3892/etm.2020.9078
  • Pages: 3114-3121
  • Copyright: © Lei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Allergic rhinitis (AR) is the allergic inflammation of immune cells in the nasal mucosa, caused by an abnormal T‑cell response. Interleukin (IL)‑37, a unique member of the IL‑1 family with broad anti‑inflammatory roles in various autoimmune diseases, participates in the immune regulation of AR. However, the regulatory mechanism of IL‑37 in AR has remained elusive. In the present study, a mouse model of AR was established by treating mice with ovalbumin (OVA). Following systemic administration of IL‑37, the effects of the cytokine on allergic symptoms were evaluated. The nasal mucosal infiltration of eosinophils was assessed by histopathological observation. The serum and nasal lavage fluid concentrations of immunoglobulin (Ig)E, IgG1, IgG2a, interferon (IFN)‑γ, IL‑4, IL‑13, IL‑17a and C‑C motif cytokine ligand (CCL)11 were determined by ELISA. Treatment with OVA resulted in allergic symptoms, including enhanced eosinophil infiltration in the nasal mucosa, increased thickness of the nasal mucosa and increased levels of IgE, IgG1, IgG2a, IL‑4, IL‑13, IL‑17a and CCL11, but the level of IFN‑γ was indicated to decrease. After IL‑37 treatment, the frequency of nasal rubbing and sneezing was reduced compared with that in the OVA group. IL‑37 administration also decreased the number of eosinophils in the nasal mucosa and the thickness of the nasal mucosa, as well as the serum and nasal lavage fluid levels of IgE, IgG1, IgG2a, IL‑4, IL‑13, IL‑17a and CCL11, but the level of IFN‑γ decreased. In addition, the OVA‑induced increases in histamine and substance P levels were reversed by IL‑37 administration. CCL11 expression levels were correlated with the expression levels of IFN‑γ, IL‑4, IL‑13, IL‑17a, histamine and substance P. In conclusion, IL‑37 alleviated the OVA‑induced allergic symptoms and allergic inflammatory response by reducing the serum cytokine levels via decreasing CCL11 expression levels in mice.
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lei H, Sun Y and Quan S: IL‑37 relieves allergic inflammation by inhibiting the CCL11 signaling pathway in a mouse model of allergic rhinitis. Exp Ther Med 20: 3114-3121, 2020.
APA
Lei, H., Sun, Y., & Quan, S. (2020). IL‑37 relieves allergic inflammation by inhibiting the CCL11 signaling pathway in a mouse model of allergic rhinitis. Experimental and Therapeutic Medicine, 20, 3114-3121. https://doi.org/10.3892/etm.2020.9078
MLA
Lei, H., Sun, Y., Quan, S."IL‑37 relieves allergic inflammation by inhibiting the CCL11 signaling pathway in a mouse model of allergic rhinitis". Experimental and Therapeutic Medicine 20.4 (2020): 3114-3121.
Chicago
Lei, H., Sun, Y., Quan, S."IL‑37 relieves allergic inflammation by inhibiting the CCL11 signaling pathway in a mouse model of allergic rhinitis". Experimental and Therapeutic Medicine 20, no. 4 (2020): 3114-3121. https://doi.org/10.3892/etm.2020.9078